Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 6:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 1,706 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS) Clear all

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 22
States / cities: Phoenix, Arizona • Harbor City, California • Irvine, California + 17 more

Conditions: HIV Infections, Cardiovascular Disease
Interventions: Not listed
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: HIV Infections
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: Not listed
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Immunodeficiency Virus Type 1, Human
Interventions: Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC, DRV/COBI FDC, FTC/TDF FDC, D/C/F/TAF FDC - Matching Placebo, FTC/TDF FDC Matching Placebo, DRV/COBI FDC Matching Placebo; Drug
Lead sponsor: Janssen Sciences Ireland UC; Industry
Eligibility: 18 Years and older
Enrollment: 725 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 29
States / cities: Birmingham, Alabama • Phoenix, Arizona • Bakersfield, California + 26 more

Conditions: Cardiovascular Diseases, Hepatitis C, Hiv
Interventions: Elbasvir / Grazoprevir Oral Tablet [Zepatier], Cardiac MRI; Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 80 Years
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Baltimore, Maryland

Conditions: HIV Infections
Interventions: Nelfinavir; Drug
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Timeline: 2003 – 2005
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: HIV, Coronary Artery Disease
Interventions: metformin extended release; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 45 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: HIV Infection
Interventions: HPV vaccine for strains -6, -11, -16, and -18; Biological
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 16 Years to 23 Years · Female only
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Fort Lauderdale, Florida + 9 more

Conditions: Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions: Rifabutin; Drug
Lead sponsor: Pharmacia; Industry
Eligibility: 18 Years and older
Enrollment: 750 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 31
States / cities: Phoenix, Arizona • Berkeley, California • Beverly Hills, California + 22 more

Conditions: HIV Infections
Interventions: HIV-1 Peptide Vaccine, Microparticulate Monovalent, rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine; Biological
Lead sponsor: United Biomedical; Industry
Eligibility: 18 Years to 50 Years
Healthy volunteers: Accepts healthy volunteers
U.S. locations: 1
States / cities: San Francisco, California

Conditions: HIV-1-infection
Interventions: On the Dot Mobile app; Behavioral
Lead sponsor: Environment and Health Group, Inc.; Industry
Eligibility: 30 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: HIV Infections
Interventions: Zidovudine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Ends 1989
U.S. locations: 23
States / cities: La Jolla, California • Los Angeles, California • San Diego, California + 13 more

Conditions: HIV Infections
Interventions: Raltegravir + Truvada; Drug
Lead sponsor: David A Wohl, MD; Other
Eligibility: 18 Years and older
Enrollment: 38 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 2
States / cities: Chapel Hill, North Carolina • Winston-Salem, North Carolina

Conditions: Papillomatosis, HIV Infections
Interventions: Interferon-alpha, placebo; Drug · Other
Lead sponsor: Ainos, Inc. (f/k/a Amarillo Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 12
States / cities: San Francisco, California • Fort Lauderdale, Florida • Augusta, Georgia + 9 more

Conditions: HIV-1-infection, Acute HIV Infection
Interventions: Not listed
Lead sponsor: AIDS Healthcare Foundation; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Human Immunodeficiency Virus, Stigma, Social, Patient Engagement
Interventions: A set of implementation strategies to reduce sexual stigma; Behavioral
Lead sponsor: Albert Einstein College of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 113 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: HIV Infections
Interventions: Pembrolizumab; Drug
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Hypertriglyceridemia, HIV Infection
Interventions: Lovaza, fosamprenavir/ritonavir; Dietary Supplement · Drug
Lead sponsor: Felizarta, Franco, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Bakersfield, California

Conditions: Human Immunodeficiency Virus, Human Papillomavirus- 6, 11, 16, 18, Adolescent, Papillomavirus Vaccines
Interventions: Gardasil, Survey; Biological · Behavioral
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 12 Years to 26 Years
Enrollment: 26 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Latent Tuberculosis
Interventions: Not listed
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years and older
Enrollment: 157 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2016
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: HIV Infections
Interventions: VH3810109, Cabotegravir, Standard of care (SOC), rHuPH20; Biological · Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 43
States / cities: Birmingham, Alabama • Bakersfield, California • Los Angeles, California + 35 more

Conditions: Inflammation in HIV Infection
Interventions: arabinoxylan rice bran, Placebo for arabinoxylan rice bran; Dietary Supplement
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Human Immunodeficiency Virus, Hypertension
Interventions: Task-shifting strategy for HTN control (TASSH) protocol; Behavioral
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 830 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Mycobacterium Avium-Intracellulare Infection, HIV Infections
Interventions: Rifapentine, Ethambutol hydrochloride, Clarithromycin, Azithromycin; Drug
Lead sponsor: Anderson Clinical Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Hampton, Virginia

Search by objective public record fields.

A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS

HIV and Cardiovascular Risk

Immune Response to Influenza Vaccine in HIV-Infected Individuals

A Study to Evaluate Efficacy and Safety of Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) Fixed Dose Combination (FDC) Versus a Regimen Consisting of Darunavir/Cobicistat FDC With Emtricitabine/Tenofovir Disoproxil Fumarate FDC in Treatment-naive HIV Type 1 Infected Subjects

Cardiovascular Disease in HIV and Hepatitis C: Risk Outcomes After Hepatitis C Eradication

Nelfinavir and M8 Drug-level Monitoring in HIV-1 Infection

Metformin for HIV Inflammation

Impact of a Human Papilloma Virus (HPV) Vaccine in HIV-Infected Young Women

Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial

A Phase I/II Safety and Immunogenicity Trial of UBI Microparticulate Monovalent (HIV-1 MN) Branched Peptide Vaccine in HIV-1 Seronegative Human Subjects

mHealth for ART Adherence by HIV+ African Americans

The Safety and Effectiveness of Zidovudine (AZT) in the Treatment of HIV Infection in Patients With AIDS and Advanced ARC

Raltegravir as Early Therapy in African-Americans Living With HIV Study

Treatment of Oral Warts in HIV+ Patients

Specimen Repository for HIV Immunopathogenesis

Mitigating Sexual Stigma Within Healthcare Interactions Improve Engagement of MSM in HIV Prevention

PD-1 Inhibition to Determine CNS Reservoir of HIV-Infection

Boosted Lexiva With Lovaza Adjunctive Therapy in Hypertriglyceridemic, HIV-Infected Subjects

A Phase I Study of Quadrivalent Human Papilloma Virus (HPV) (Types 6, 11, 16, 18) Recombinant Vaccine in HIV-Infected and HIV-Negative Pre-Adolescents, Adolescents, and Young Adults

Immune Response to Mycobacterium Tuberculosis Infection

A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)

Rice Bran Supplementation in Treated HIV Infection

Integration of Hypertension Management Into HIV Care in Nigeria

Tolerance, Safety, and Activity of Rifapentine Alone and in Combination Therapy in AIDS Patients With Mycobacterium Avium Complex Bacteremia.